Variability of polymyxin B major components in commercial formulations

International Journal of Antimicrobial Agents

Volumn 35, Issue 3, 2010, Pages 308-310

  He, Jie ^a   Ledesma, Kimberly R ^a   Lam, Wai Ying ^a   Figueroa, Deborah A ^b   Lim, Tze Peng ^c   Chow, Diana S L ^a   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b NEW YORK HOSPITAL QUEENS   (United States)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMYXIN B;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; BROTH DILUTION; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KLEBSIELLA PNEUMONIAE; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ULTRAVIOLET SPECTROSCOPY;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; POLYMYXIN B;

EID: 73549119238     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.11.005     Document Type: Letter

References (7)

1. Sobieszczyk M.E., Furuya E.Y., Hay C.M., Pancholi P., Della-Latta P., Hammer S.M., et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 54 (2004) 566-569
2. Orwa J.A., Govaerts C., Busson R., Roets E., Van Schepdael A., and Hoogmartens J. Isolation and structural characterization of polymyxin B components. J Chromatogr A 912 (2001) 369-373
3. Tam V.H., Hou J., Kwa A.L., and Prince R.A. Comment on: development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother 63 (2009) 627-628 [Author reply 628-9]
4. Yuan Z., and Tam V.H. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs 17 (2008) 661-668
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. Document M100-S17. Wayne, PA: CLSI; 2007.
6. Ouderkirk J.P., Nord J.A., Turett G.S., and Kislak J.W. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 47 (2003) 2659-2662
7. Zavascki A.P., Goldani L.Z., Cao G., Superti S.V., Lutz L., Barth A.L., et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47 (2008) 1298-1304